Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pediatric subjects older than 12 years of age and adult subjects with asthma
Subjects who will administer ARNUITY in accordance with the product information approved in Korea
Subjects who have signed the informed consent form for the PMS
You may not be if
Subjects with status asthmaticus or subjects who have administered ARNUITY as primary therapy for other acute asthmatic episodes that require intensive treatment
Subjects who have any known hyper-sensitivity to the drug or its ingredients
Subjects who have severe hypersensitive reactions to milk proteins
Subjects with hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption
Clareo Health | Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting
